Global Meningitis Deaths Exceed 250,000, Prompting Urgent Calls for UK Teen Catch-Up Jabs
A stark new report has unveiled that meningitis claimed more than 250,000 lives worldwide in 2023, a figure described as "alarming" by health authorities. The findings have spurred urgent demands for the UK to enhance its vaccination strategy, specifically through implementing a catch-up service for teenagers who missed their MenACWY immunisations.
UK Cases and the Persistent Global Threat
According to The Lancet Neurology report, which meticulously details the global impact of this deadly infection, the UK recorded 5,150 meningitis cases and 159 fatalities in 2023. While global deaths have seen a decline since 1990, experts warn that progress remains "insufficient" to meet the World Health Organization's ambitious 2030 targets. These goals aim to slash global incidence by 50 percent and deaths by 70 percent, using 2015 as a baseline.
Olivier Picard, Chair of the National Pharmacy Association, emphasised the gravity of the situation, stating, "This is an alarming report. It's clear there are gaps in the original national vaccination strategy for meningitis and pharmacies want to reach those in need of protection." He called for the NHS to urgently commission pharmacies to provide a catch-up vaccination service for teenagers and to support wider childhood immunisation efforts.
Vaccination Gaps and Recent Outbreaks
Dr Tom Nutt, chief executive of Meningitis Now, described the data as a "wake-up call" for governments to prioritise vaccination. "Vaccines are one of the most effective tools we have to prevent meningitis, yet uptake and access remain inconsistent across the world – and there is more we must do here in the UK too," he asserted. He highlighted a recent meningitis B outbreak in Kent, which resulted in 20 cases and two deaths, as evidence that even the UK's advanced vaccination programme has vulnerabilities, particularly for teenagers and young adults.
Over the past two decades, England has witnessed a significant decline in bacterial meningitis cases, dropping from 2,595 in 1999 to 378 in 2024, largely due to the introduction of the MenACWY vaccine. This vaccine has been available to teenagers and university entrants up to age 25 since 2015, while babies receive the meningitis B vaccine, each targeting different strains.
Expert Insights on Vaccine Efficacy and Socioeconomic Factors
Professor Martin Maiden, an epidemiologist at Oxford University, explained that the MenACWY vaccine is "tremendously successful" and primarily works through herd protection. In contrast, the MenB vaccine offers only individual protection. "We know it won't interrupt transmission, but it might stop some cases," he told The Independent. "There's one view that this is such a terrible disease, you must do anything to stop any single case. And there's another view that says, we have limited resources in the health service."
Professor Paul Hunter, an epidemiologist at the University of East Anglia, noted that UK cases remain below the global average but suggested that beyond immunisation, "reducing poverty" could "make a real difference." Referencing his 2004 study, he pointed out that cases are roughly twice as high in the most deprived third of electoral wards compared to the rest of society.
Path Forward and WHO Goals
Dr Shamez Ladhani, a consultant epidemiologist at the UK Health Security Agency, affirmed, "Vaccines have transformed our ability to protect people from bacterial meningitis, and the UK has invested significantly in immunisation programmes for those at highest risk." He stressed ongoing collaboration with the NHS and partners to boost uptake across all age groups.
"Achieving the WHO's 'Defeating Meningitis by 2030' goals will require continued collaboration – expanding vaccination, strengthening diagnostics, and ensuring that wherever gaps exist, we work to close them," Dr Ladhani added. The NHS and the Department for Health and Social Care have been approached for comment on these urgent calls to action.
